Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosimo Durante

Showing results (121-130 of 175) with videos related to

Pageof 18
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 13, 2007
Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patientsMassimo Torlontano, Cosimo Durante, Isabella Torrente, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2012
Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?Cosimo Durante, Teresa Montesano, Marco Attard, et al.
Molecular and Cellular Endocrinology|March 15, 2017
Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cellsValentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, et al.
Clinical Endocrinology|September 6, 2012
A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytomaAngela V D'Elia, Franco Grimaldi, Stefano Pizzolitto, et al.
Endocrine|June 17, 2011
Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian familySandra Mastroianno, Massimo Torlontano, Alfredo Scillitani, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?Livia Lamartina, Teresa Montesano, Rosa Falcone, et al.
Clinical Endocrinology|December 31, 2009
A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterizationMaria D Castellone, Antonella Verrienti, Deva Magendra Rao, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 7, 2015
A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2Antonella Verrienti, Antonella Carbone, Pasquale Bellitti, et al.
Endocrine|January 26, 2017
Expression of YAP1 in aggressive thyroid cancerMarilena Celano, Chiara Mignogna, Francesca Rosignolo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Papillary thyroid cancer: time course of recurrences during postsurgery surveillanceCosimo Durante, Teresa Montesano, Massimo Torlontano, et al.
Pageof 18

Showing results (121-130 of 175) with videos related to

Sort By:
Pageof 18
The Journal of Clinical Endocrinology and Metabolism|December 13, 2007
Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patientsMassimo Torlontano, Cosimo Durante, Isabella Torrente, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2012
Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?Cosimo Durante, Teresa Montesano, Marco Attard, et al.
Molecular and Cellular Endocrinology|March 15, 2017
Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cellsValentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, et al.
Clinical Endocrinology|September 6, 2012
A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytomaAngela V D'Elia, Franco Grimaldi, Stefano Pizzolitto, et al.
Endocrine|June 17, 2011
Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian familySandra Mastroianno, Massimo Torlontano, Alfredo Scillitani, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?Livia Lamartina, Teresa Montesano, Rosa Falcone, et al.
Clinical Endocrinology|December 31, 2009
A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterizationMaria D Castellone, Antonella Verrienti, Deva Magendra Rao, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 7, 2015
A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2Antonella Verrienti, Antonella Carbone, Pasquale Bellitti, et al.
Endocrine|January 26, 2017
Expression of YAP1 in aggressive thyroid cancerMarilena Celano, Chiara Mignogna, Francesca Rosignolo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Papillary thyroid cancer: time course of recurrences during postsurgery surveillanceCosimo Durante, Teresa Montesano, Massimo Torlontano, et al.
Pageof 18